| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f57229ef2102805e4b773d3848ea7d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6582742e4bec2d62f0a2b1c1dfdc7c36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42245de6a84e559f56c4f0fc19d9cf46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1273 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2005-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f9acad048e8747a42061c801b10867f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6a0507e9bd72a392bbc98c0118d2dcc |
| publicationDate |
2006-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006051549-A2 |
| titleOfInvention |
Combination therapy associating preferably a ceramide with a cytotoxic drug |
| abstract |
The present invention concerns a new medical treatment involving the combination of two active entities, as well as pharmaceutical compositions comprising the two active entities. Specifically, the invention provides a pharmaceutical composition comprising a stable lipid assembly comprising as a first active entity an apoptosis-affecting lipid which does not self-aggregate in a polar environment to form liposomes and a lipopolymer. The pharmaceutical composition further comprises, as the second active entity, a cytotoxic amphipathic weak base drug carried by the lipid assembly or by a different liposome. According to one embodiment, the apoptotic-affecting lipid is a pro-apoptotic lipid. A preferred pro-apoptotic lipid is ceramide, preferably C6-ceramide. The cytotoxic amphipathic weak base drug is preferably doxorubicin or a biologically active, anthracyline-based doxorubicin analog thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10052387-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109350600-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014144421-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014167126-A3 |
| priorityDate |
2004-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |